ArticlePloS one2017
IGFN1_v1 is required for myoblast fusion and differentiation.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Meta-Analysis of RNA-Seq Data Identifies Differentially Expressed Genes in Skeletal Muscle Between Obese and Normal Weight Individuals.International journal of molecular sciences · 2026Pooled it
- Meta-analysis of endometrial transcriptome data reveals novel molecular targets for recurrent implantation failure.Journal of assisted reproduction and genetics · 2024Pooled it
- Identification of Growth-Related Key Genes Based on Nonlinear Fitting of Weight Growth Curves in Min Pigs.Animals : an open access journal from MDPI · 2026Article
- Phosphoproteomics Preliminarily Revealed the Differential Phosphorylation Sites and Their Functional Significance in the Longissimus Dorsi Muscle of Kazakh and Xinjiang Brown Cattle.Food science & nutrition · 2026Article
- Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.Journal of cachexia, sarcopenia and muscle · 2026Observational
- Molecular insight into transcriptome profiling of aerobic exercise induced changes in aged skeletal muscle.npj aging · 2026Article
- 1,24,25(OH)Scientific reports · 2025Article
- Preliminary Study on the Genetic Structure and Functional Candidate Genes of Grassland-Thoroughbreds Based on Whole-Genome Resequencing.Animals : an open access journal from MDPI · 2025Article
- Whole-Genome Resequencing Analysis of Copy Number Variations Associated with Athletic Performance in Grassland-Thoroughbred.Animals : an open access journal from MDPI · 2025Article
- Integrated transcriptomic, proteomic, and metabolomic analysis unveils key roles of protein and nucleic acid interactions in diabetic ulcer pathogenesis.Frontiers in endocrinology · 2025Article
- HDL levels modulate the impact of type 2 diabetes susceptibility alleles in older adults.Lipids in health and disease · 2024Article
- The alteration of LBX1 expression is associated with changes in parameters related to energy metabolism in mice.PloS one · 2024Article
- Genome- and Exome-Wide Association Studies Revealed Candidate Genes Associated with DaTscan Imaging Features.Parkinson's disease · 2023Article
- Single nuclei profiling identifies cell specific markers of skeletal muscle aging, frailty, and senescence.Aging · 2022Article
- Rehabilitative Impact of Exercise Training on Human Skeletal Muscle Transcriptional Programs in Parkinson's Disease.Frontiers in physiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Igfn1 is a complex locus that codes for multiple splicing variants of Immunoglobulin- and Fibronectin-like domain containing proteins predominantly expressed in skeletal muscle. To reveal possible roles for Igfn1, we applied non-selective knock-down by shRNAs as well as specific targeting of Igfn1 exon 13 by CRISPR/Cas9 mutagenesis in C2C12 cells. Decreased expression of Igfn1 variants via shRNAs against the common 3'-UTR region caused a total blunting of myoblast fusion, but did not prevent expression of differentiation markers. Targeting of N-terminal domains by elimination of exon 13 via CRISPR/Cas9 mediated homologous recombination, also resulted in fusion defects as well as large multinucleated cells. Expression of IGFN1_v1 partially rescued fusion and myotube morphology in the Igfn1 exon 13 knock-out cell line, indicating a role for this variant in myoblast fusion and differentiation. However, in vivo overexpression of IGFN1_v1 or the Igfn1 Exon 13 CRISPR/Cas9 targeting vector did not result in significant size changes in transfected fibres.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.